Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype

被引:34
|
作者
Sidney, J
Southwood, S
Pasquetto, V
Sette, A
机构
[1] La Jolla Inst Allergy & Immunol, Div Translat Immunol & Biodef, San Diego, CA 92121 USA
[2] Epimmune Inc, San Diego, CA 92121 USA
来源
JOURNAL OF IMMUNOLOGY | 2003年 / 171卷 / 11期
关键词
D O I
10.4049/jimmunol.171.11.5964
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We selected for study a set of B44-supertype molecules collectively represented in >40% of the individuals in all major ethnicities (B*1801, B*4001, B*4002, B*4402, B*4403, and B*4501). The peptide-binding specificity of each molecule was characterized using single amino acid substitution analogues and nouredundant peptide libraries. In all cases, only peptide ligands with glutamic acid in position 2 were preferred. At the C terminus, each allele was associated with a unique but broad pattern of preferences, but all molecules tolerated hydrophobic/aliphatic (leucine, isoleucine, valine, methionine), aromatic (tyrosine, phenylalanine, tryptophan), and small (alanine, glycine, threonine) residues. Secondary anchor motifs were also defined for all molecules. Together, these features were used to define a B44 supermotif and a novel algorithm for calculating degeneracy scores that can be used to predict B44-supertype degenerate binders. Approximately 90% of the peptides with a B44 supermotif degeneracy score of >10 bound at least three of the six B44-supertype molecules studied with high affinity. Finally, a number of peptides derived from hepatitis B and C viruses, HIV, and Plasmodium falciparum have been identified that have degenerate B44 supertype-binding capacity. Taken together, these findings have important implications for epitope-based approaches to vaccination, immunotherapy, and the monitoring of immune responses.
引用
收藏
页码:5964 / 5974
页数:11
相关论文
共 50 条
  • [1] HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy
    Cummings, A.
    Lu, H.
    Gukasyan, J.
    Madrigal, J.
    Carroll, J.
    Bornazyan, K.
    Jones, B.
    Noor, Z.
    Lisberg, A.
    Goldman, J. W.
    Hu-Lieskovan, S.
    Dubinett, S.
    Baron, E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S530 - S531
  • [2] Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).
    Lu, Henry
    Cummings, Amy Lauren
    Goldman, Jonathan Wade
    Lisberg, Aaron Elliott
    Hu-Lieskovan, Siwen
    Grogan, Tristan
    Gukasyan, Jaklin
    Madrigal, John
    Carroll, James M.
    Bornazyan, Krikor
    Jones, Benjamin
    Noor, Zorawar Singh
    Zaretsky, Jesse Meir
    Elashoff, David
    Slamon, Dennis J.
    Dubinett, Steven M.
    Garon, Edward B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] MATERNAL HLA B44 PREDISPOSES TO MATERNALLY TRANSMITTED SCHIZOPHRENIA
    WRIGHT, P
    WARD, AJ
    DOHERTY, DG
    DONALDSON, PT
    UNDERHILL, JA
    GILL, M
    MURRAY, RM
    [J]. SCHIZOPHRENIA RESEARCH, 1994, 11 (02) : 147 - 148
  • [4] Analysis of TACI mutations in CVID patients with HLA*B44
    Waldrep, M. L.
    Schroeder, H. W.
    Zhang, Y.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (01) : A53 - A53
  • [5] Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype
    Hillen, Nina
    Mester, Gabor
    Lemmel, Claudia
    Weinzierl, Andreas O.
    Mueller, Margret
    Wernet, Dorothee
    Hennenlotter, Joerg
    Stenzl, Arnulf
    Rammensee, Hans-Georg
    Stevanovic, Stefan
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (11) : 2993 - 3003
  • [6] HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN)
    Ozawa, A
    Sasao, Y
    Iwashita, K
    Miyahara, M
    Sugai, J
    Iizuka, M
    Kawakubo, Y
    Ohkido, M
    Naruse, T
    Anzai, T
    Takashige, N
    Ando, A
    Inoko, H
    [J]. TISSUE ANTIGENS, 1999, 53 (03): : 263 - 268
  • [7] Definition of the HLA-B44 supertype from natural ligand repertoires
    不详
    [J]. IMMUNOBIOLOGY, 2005, 210 (6-8) : 547 - 547
  • [8] HLA B44 subtyping by DGGE: A sensitive and rapid new approach to HLA class I typing
    Tamouza, R
    Marzais, F
    Krishnamoorthy, R
    Gordien, E
    Besmond, C
    Raffoux, C
    Charron, D
    [J]. HUMAN IMMUNOLOGY, 1996, 47 (1-2) : O216 - O216
  • [9] ASSOCIATION OF CROHNS-DISEASE WITH THE HLA PHENOTYPE B44, CW5
    PURRMANN, J
    BERTRAMS, J
    CLEVELAND, S
    GEMSA, R
    BERGES, W
    STROHMEYER, G
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1988, 26 (10): : 658 - 662
  • [10] A novel HLA-B*44 allele, HLA-B*4459, identified in a renal patient with aberrant B44 serology and characterized by sequence-based typing
    Hammond, L.
    Dunn, P. P. J.
    [J]. TISSUE ANTIGENS, 2008, 72 (05): : 494 - U6